The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.

Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...

Bladder control problems, or urinary incontinence, can cause an uncontrolled urgency to urinate, increased visits to the bathroom, and accidental leakage. Different medical conditions, aging, and ...

Urge incontinence (sudden leaking of urine) When lifestyle and behavioral modifications fail, multiple other treatment options are available. The medications most commonly taken for OAB are ...

Treatment with vibegron reduced the average number of micturition episodes per day and the average number of daily urgency episodes compared with placebo. The Food and Drug Administration (FDA ...

The standard treatments for overactive bladder include lifestyle changes, bladder training, pelvic floor muscle training and anticholinergic (anti-muscarinic) drugs. Additional treatments for some ...

The US subsidiary of Japan’s Sumitomo Pharma announced that the US Food and Drug Administration (FDA) has approved Gemtesa ...